Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biotechnology

NJEDA: Ideal Location, Unique State Resources Give Enteris BioPharma Advantage in Global Marketplace

Trenton, NJ, June 25, 2017 — This week’s BIO International Convention gave leaders from New Jersey’s vast life sciences ecosystem the chance to show emerging companies the advantages of establishing themselves within the State, such as its ideal location on the Eastern seaboard and the large number of pharmaceutical giants that currently call the State “home.”

“The Garden State is truly the best place to start a biopharmaceutical company,” New Jersey Economic Development Authority (EDA) Chief Executive Officer (CEO) Melissa Orsen said. Continue reading

BIO International Convention 2017 Closes After Four ‘Breakthrough’ Days in San Diego; BIO 2018 Set for Boston

Washington, DC, June 23, 2017 — The 2017 BIO International Convention (BIO 2017), hosted by the Biotechnology Innovation Organization (BIO), closed yesterday after four days of immersive, compelling programming united under the theme of “Breakthrough.”

BIO 2017 drew 16,123 biotechnology industry leaders from 48 States, the District of Columbia, Puerto Rico and 73 countries to San Diego, the “genomics capital” of the world.

As the largest global biotechnology event, BIO 2017 provided attendees with unique perspectives on the immense opportunities and complex challenges ahead for the industry. Continue reading

Choose New Jersey Showcases State’s Assets, Resources at BIO International 2017 This Week

Princeton, NJ, June 22, 2017 — A delegation representing more than 20 New Jersey organizations, including top life sciences companies, universities, trade associations, State government and Choose New Jersey, Inc. is showcasing New Jersey’s assets and resources for biotechnology companies at the New Jersey Pavilion (Booth #1737) at BIO International 2017, June 19-22 (2017) in San Diego, California.

During the world’s largest biotechnology conference, members of the New Jersey delegation are holding business meetings with executives representing companies in North America, Europe and Asia interested in learning more about the benefits of a New Jersey location. Continue reading

Opinion: Assemblyman Gary Schaer on ‘A Blueprint for Tomorrow’

Asm. Gary Schaer

Trenton, NJ, June 20, 2017Assemblyman Gary S. Schaer (D-Passaic), Chair of the Assembly Budget Committee, last month shared the following with Innovation New Jersey readers:

Each time we tackle the state budget, we are reminded that it is a living, breathing document that, at its core, should fundamentally reflect our priorities.  As we enter final deliberations in crafting this year’s state budget, that reminder is all the more potent.

One of the reasons New Jersey’s economy lagged far behind most of the nation after the Great Recession is because we failed to make the proper investments to capitalize on our strengths and leverage our assets to grow our economy.  We cannot expect to move forward and grow as a state without planting the proper seeds.  Continue reading

Opinion: Former Merck CEO and Princeton University President Emeritus on ‘Trump’s War on Science Threatens U.S. Prosperity’

Princeton, NJ, June 12, 2017Roy Vagelos, retired Chairman and CEO of Merck & Co. and Chairman of the Board of Regeneron Pharmaceuticals, and Shirley Tilghman, President Emeritus of Princeton University and a professor of Molecular Biology and Public Affairs, published the following opinion piece in The Star-Ledger on June 6:

In the past 40 years, the U.S. has been the world leader in converting fundamental scientific discoveries into innovative new treatments for life-threatening disease.  New drugs, vaccines, and medical devices have improved human health and increased our lifespan. Continue reading

HINJ to Serve as Lead Sponsor of Choose New Jersey’s Annual Reception at BIO International on June 19 in San Diego

New Brunswick, NJ, May 19, 2016 — The HealthCare Institute of New Jersey (HINJ) will serve, once again, as the lead sponsor of Choose New Jersey’s annual reception at BIO International Convention on Monday, June 19 from 5:00 to 7:00 p.m. at Top of the Hyatt at the Grand Hyatt San Diego.

Choose New Jersey will showcase top life sciences companies, universities, trade associations, the State government at its New Jersey Pavilion (Booth #1737) at BIO International 2017, which will be held from June 19 to 22 at the San Diego Convention Center. Continue reading

Event: BioNJ to Partner with J.P. Morgan on 7th Annual BioPartnering Conference on May 23

Trenton, NJ, May 9, 2017 — In partnership with J.P. Morgan, BioNJ will host its Seventh Annual BioPartnering Conference on Tuesday, May 23, 2017, from 8:00 a.m. to 5:00 p.m. at the Busch Campus Center at Rutgers University in Piscataway.

The event is expected to bring together over 200 regional biopharmaceutical executives, investors, academic collaborators and business development professionals for a day of networking, 1-1 partnering meetings, company presentations, exhibits and plenary sessions.

“We’re thrilled to be partnering with J.P. Morgan on this year’s BioPartnering Conference,” said Debbie Hart, President and CEO, BioNJ. Continue reading

BIO Offers Video Explaining How Drug Costs Are Really Determined

Washington, DC, April 3, 2017 — Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen.

However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.

To help put this debate into context, the Biotechnology Innovation Organization (BIO) in October unveiled an educational video today designed to give patients, consumers, policy makers and journalists a better understanding of how prescription drug costs are really determined and where the pharmaceutical dollar actually goes. Continue reading

Biotechnology Innovation Organization Statement on President’s Budget Proposal

Washington, DC, March 20, 2017Biotechnology Innovation Organization (BIO) Senior Vice President for Communications Kenneth Lisaius issued the following statement on March 17 regarding President Donald J. Trump’s budget blueprint:

“While we are still reviewing today’s budget blueprint, we have initial concerns with the proposed reductions in the budgets for biomedical research, public health, and for agencies that play an important role in promoting innovations in agricultural, environmental, and human health.

“We are encouraged by other language in the budget blueprint that seeks to improve the regulatory environment for such innovations. Continue reading

NJEDA’s Angel Investor Tax Credit Fuels Investment in NJ Biotechnology Firms

Trenton, NJ, March 1, 2017New Jersey Business reports that New Jersey’s Angel Investor Tax Credit Program boosted investment in local tech firms to a record number in 2016.

As Lilo Stainton reported in the news website NJ Spotlight, the NJ Economic Development Authority (EDA) approved 251 applications for angel investor tax credits that spurred more than $96 million in private investments, the highest annual total since the program was launched three years ago. Continue reading